In a report released today, Yaron Werber from Cowen & Co. reiterated a Buy rating on Acceleron Pharma (XLRN – Research Report), with a price target of $78. The company’s shares closed last Monday at $44.65.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 9.6% and a 58.6% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Prevail Therapeutics Inc.
Currently, the analyst consensus on Acceleron Pharma is a Moderate Buy with an average price target of $60.83, representing a 39.8% upside. In a report issued on September 6, H.C. Wainwright also maintained a Buy rating on the stock with a $69 price target.
The company has a one-year high of $59.59 and a one-year low of $37.01. Currently, Acceleron Pharma has an average volume of 285.9K.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is neutral on the stock. Most recently, in July 2019, John Quisel, the EVP, Chief Business Officer of XLRN bought 8,908 shares for a total of $42,908.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maneates in June 2003 and is headquartered in Cambridge, MA.